Development of clinical pathway in S-1 chemotherapy for gastric cancer.
We have developed a clinical pathway to enable the safe continuous administration of S-1 (TS-1) in ambulatory care for patients with advanced gastric cancer. The S-1 clinical pathway includes a pathway for clinicians, a pathway for patients, and such assist tools as a medication diary, an explanatory document containing instructions relating to patient compliance, a table of associations between adverse reactions and prodromes, and general principles for dose reduction and withdrawal. These pathways and assist tools will improve the patient's perception of adverse reactions, thereby contributing to early discovery and rapid action against adverse events. The S-1 clinical pathway has been used with ten patients. S-1 administration has been continued in seven patients. In four of the seven patients, continued administration on the occurrence of adverse reactions was made possible by the use of appropriate measures such as drug withdrawal or dose reduction. It was confirmed that the S-1 clinical pathway was a useful tool for cancer chemotherapy in ambulatory care.
Noie
Tamaki
T
Department of Surgery, Kanto Medical Center NTT East, 5-9-22 Higashi-gotanda, Shinagawa-ku, Tokyo 141-8625, Japan.
Konishi
Toshiro
T
Nara
Satoshi
S
Ito
Kei
K
Harihara
Yasushi
Y
Furushima
Kaoru
K
D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000592:standards*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D019091:Critical Pathways; D018450:Disease Progression; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects; D011785:Quality Assurance, Health Care; D017751:Safety Management; D012646:Self Administration / Q000592:standards; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000523:psychology; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D028761:Withholding Treatment
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid